The Experts below are selected from a list of 223068 Experts worldwide ranked by ideXlab platform

Gerald Steinmaurer - One of the best experts on this subject based on the ideXlab platform.

Alois Resch - One of the best experts on this subject based on the ideXlab platform.

Patrick Kefer - One of the best experts on this subject based on the ideXlab platform.

Mark Emberton - One of the best experts on this subject based on the ideXlab platform.

  • new and Established Technology in focal ablation of the prostate a systematic review
    European Urology, 2017
    Co-Authors: Massimo Valerio, Y Cerantola, Scott E Eggener, Herbert Lepor, Thomas J Polascik, Arnauld Villers, Mark Emberton
    Abstract:

    Abstract Context Focal therapy of prostate cancer has been proposed as an alternative to whole-gland treatments. Objective To summarize the evidence regarding sources of energy employed in focal therapy. Evidence acquisition Embase and Medline (PubMed) were searched from 1996 to October 31, 2015 following the Preferred Reporting Items for Systematic Reviews and Meta-analyses statement. Ongoing trials were selected from electronic registries. The stage of assessment of each source of energy was determined using the Idea, Development, Exploration, Assessment, Long-term study recommendations. Evidence synthesis Thirty-seven articles reporting on 3230 patients undergoing focal therapy were selected. Thirteen reported on high-intensity focused ultrasound, 11 on cryotherapy, three on photodynamic therapy, four on laser interstitial thermotherapy, two on brachytherapy, three on irreversible electroporation, and one on radiofrequency. High-intensity focused ultrasound, cryotherapy, photodynamic therapy, and brachytherapy have been assessed in up to Stage 2b studies. Laser interstitial thermotherapy and irreversible electroporation have been evaluated in up to Stage 2a studies. Radiofrequency has been evaluated in one Stage 1 study. Median follow-up varied between 4 mo and 61 mo, and the median rate of serious adverse events ranged between 0% and 10.6%. Pad-free leak-free continence and potency were obtained in 83.3–100% and 81.5–100%, respectively. In series with intention to treat, the median rate of significant and insignificant disease at control biopsy varied between 0% and 13.4% and 5.1% and 45.9%, respectively. The main limitations were the length of follow-up, the absence of a comparator arm, and study heterogeneity. Conclusions Focal therapy has been evaluated using seven sources of energy in single-arm retrospective and prospective development studies up to Stage 2b. Focal therapy seems to have a minor impact on quality of life and genito-urinary function. Oncological effectiveness is yet to be defined against standard of care. Patient summary Seven sources of energy have been employed to selectively ablate discrete areas of prostate cancer. There is high evidence that focal therapy is safe and has low detrimental impact on continence and potency. The oncological outcome has yet to be evaluated against standard of care.

Dmitry Oleynikov - One of the best experts on this subject based on the ideXlab platform.

  • Recent in vivo surgical robot and mechanism developments
    Surgical Endoscopy and Other Interventional Techniques, 2007
    Co-Authors: Mark E Rentschler, Dmitry Oleynikov
    Abstract:

    The surgical landscape is quickly changing because of the major driving force of robotics. Well-Established Technology that provides robotic assistance from outside the patient may soon give way to alternative approaches that place the robotic mechanisms inside the patient, whether through traditional laparoscopic ports or through other, natural orifices. While some of this Technology is still being developed, other concepts are being evaluated through clinical trials. This article examines the state of the art in surgical robots and mechanisms by providing an overview of the ex vivo robotic systems that are commercially available to in vivo mechanisms, and robotic assistants that are being tested in animal models.